Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 20/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14937367 | 0.85 | METAP2 (0.62) | METAP2 | |
| SCHEMBL436665 | 0.85 | METAP2 (0.62) | METAP2 | |
| SCHEMBL434929 | 0.80 | METAP2 (0.62) | METAP2 | |
| SCHEMBL10284179 | 0.80 | METAP2 (0.62) | METAP2 | |
| SCHEMBL10284188 | 0.80 | METAP2 (0.62) | METAP2 | |
| SCHEMBL460123 | 0.79 | METAP2 (0.62) | METAP2 | |
| SCHEMBL460122 | 0.79 | METAP2 (0.62) | METAP2 | |
| SCHEMBL15130312 | 0.78 | METAP2 (0.61) | METAP2 | |
| SCHEMBL435707 | 0.78 | METAP2 (0.57) | METAP2 | |
| SCHEMBL10283922 | 0.78 | METAP2 (0.61) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9561209-B2 | Methods of treating liver diseases | ZAFGEN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160058731-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. (US) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ENPEP, GOT2, METAP2 | METAP2 3/4885 |
| US-20160058731-A1 | METHODS OF TREATING LIVER DISEASES | ENPEP, GOT2, METAP2 | METAP2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.